Request Demo
Last update 20 Mar 2025
MBS-303
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-CD3/anti-CD20 bispecific T-cell engager(Mabworks Biotech), bispecific antibody targeting CD3 and CD20(Mabworks Biotech) + [7] |
Target |
Action inhibitors, stimulants |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with MBS-303CTR20230423
一项评价注射用MBS303治疗复发/难治性CD20阳性B细胞非霍奇金淋巴瘤的安全性、耐受性、药代动力学/药效动力学特征和有效性的I/Ⅱ期临床研究
[Translation] A Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and efficacy of MBS303 for injection in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
NCT05806099
A Phase I/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS303 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
100 Clinical Results associated with MBS-303
Login to view more data
100 Translational Medicine associated with MBS-303
Login to view more data
100 Patents (Medical) associated with MBS-303
Login to view more data
100 Deals associated with MBS-303
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-cell lymphoma refractory | Phase 2 | China | 28 Jun 2023 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 2 | China | 28 Jun 2023 | |
| Glomerular disease | IND Approval | China | 03 Sep 2024 | |
| Glomerulonephritis | IND Approval | China | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free